Press Releases

Madison, WI | October 13, 2026 – ChanPharm GmbH, a Vienna-based provider of advanced electrophysiology and drug-discovery services, today announced the publication of its proprietary CP:SphereChip™ technology for functional studies of human cardiac and neuronal spheroids and organoids in the Royal Society of Chemistry journal Lab on a Chip.

BOSTON, MA – November 18, 2025 – Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announced the launch of the Emulate Brain-Chip R1. This first-in-class comprehensive model of the neurovascular unit offers researchers a powerful new platform for studying drug transport across the blood-brain barrier (BBB) and investigating mechanisms of neuroinflammation. The Brain-Chip R1 integrates key FUJIFILM Cellular Dynamics iCell® products co-cultured with Emulate proprietary induced Brain Microvascular Endothelial Cells (iBMECs).

Madison, WI, April 29, 2025 – FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cells (iPSC), today announces the appointment of Delara Motlagh, as its new chief operating officer (COO) effective immediately. In this role, Motlagh will drive the Company’s overall business and R&D strategy while leading operational execution….

MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular….

MADISON, Wisc., September 3, 2024 – FUJIFILM Cellular Dynamics and Opsis Therapeutics congratulate BlueRock Therapeutics on receiving FDA clearance of its IND application for OpCT-001, an induced pluripotent stem cell (iPSC)-derived cell therapy candidate for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance….